Fusion Pharma Shares Move Higher After Trial Collab With Merck For IGF-1R-Expressing Cancer Study

  • Fusion Pharmaceuticals Inc FUSN has entered into a clinical trial collaboration with Merck & Co MRK to evaluate Fusion's lead candidate, FPI-1434, in combination with Merck's Keytruda in patients with solid tumors expressing insulin-like growth factor 1 receptor (IGF-1R).
  • The planned Phase 1/2 combination trial will evaluate the safety, tolerability, and pharmacokinetics of FPI-1434 in combination with pembrolizumab.
  • The study is expected to initiate approximately six to nine months after achieving the recommended Phase 2 dose in the ongoing Phase 1 study of FPI-1434 monotherapy.
  • Under the terms of the agreement, Fusion will sponsor the study, and Merck will supply Keytruda.
  • FPI-1434 is a radioimmunoconjugate designed to target and deliver alpha emitting medical isotopes to cancer cells expressing IGF-1R, a receptor that is overexpressed on many tumor types.
  • Price Action: FUSN shares are up 2.16% at $8.98 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsSmall CapGeneralBriefscancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!